Results 81 to 90 of about 4,836 (184)

Emergence of Vitiligo during Treatment with Risankizumab-Rzaa for Plaque Psoriasis: A Case Report

Case Reports in Dermatology
Introduction: Risankizumab-rzaa (Skyrizi) is a humanized monoclonal antibody (IgG1) approved for the treatment of severe plaque psoriasis.
Kevin V. Thomas, Jennifer M. Tran, Lisa M. Cotter   +2 more
doaj   +1 more source

Consistency of skin clearance with icotrokinra across patient subgroups with plaque psoriasis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Linda Stein Gold, April W. Armstrong, Ronald B. Vender, Jennifer Soung, Andrew E. Pink, Joseph Cafone, Bassey Effiom Edem, Ofelia Reyes‐Servin, Jingzhi Jiang, Kellen Cresswell, Cynthia M. C. DeKlotz, Megan Miller‐Kassamali, Ya‐Wen Yang, Mark G. Lebwohl   +13 more
wiley   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 11, Page 1669-1678, November 2026.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling

Frontiers in Immunology
IL-23 is implicated in the pathogenesis of immune-mediated inflammatory diseases, and myeloid cells that express Fc gamma receptor 1 (FcγRI or CD64) on their surface have been recently identified as a primary source of IL-23 in inflamed tissue.
Kacey L. Sachen, Deepa Hammaker, Indra Sarabia, Brian Stoveken, John Hartman, Kristin L. Leppard, Nicholas A. Manieri, Phuc Bao, Carrie Greving, Eilyn R. Lacy, Matthew DuPrie, Joshua Wertheimer, Janise D. Deming, Joseph Brown, Amy Hart, He (Hurley) Li, Tom C. Freeman, Brice Keyes, Kristen Kohler, Ian White, Nathan Karpowich, Ruth Steele, M. Merle Elloso, Steven Fakharzadeh, Kavitha Goyal, Frédéric Lavie, Maria T. Abreu, Matthieu Allez, Raja Atreya, Robert Bissonnette, Kilian Eyerich, Kilian Eyerich, James G. Krueger, Dennis McGonagle, Iain B. McInnes, Christopher Ritchlin, Anne M. Fourie   +36 more
doaj   +1 more source

Risankizumab [PDF]

Reactions Weekly, 2021
openaire   +2 more sources

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 11, Page 1831-1839, November 2026.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres, Mario Valenti, Anna Balato, Matteo Megna, Paolo Gisondi, Vimal Prajapati, Stefano Piaserico, Julia‐Tatjana Maul, Lara Valeska Maul, Jose Manuel Carrascosa, Francisco José Navarro‐Triviño, Elizabeth Lazaridou, César Ferreira, Jacopo Tartaglia, Christian Ciolfi, Athina‐Ioanna Daponte, Eugenia Veronica Di Brizzi, Maddalena Napolitano, Barbara Leal Guerra, Monica Munera‐Campos, Siddhartha Sood, Silvia Ferruci, Francesca Prignano, Esteban Dauden, Mar Llamas‐Velasco, Ron Vender, Jensen Yeung, Angelo Marzano, Luis Puig   +28 more
wiley   +1 more source

Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn’s Disease

Gastro Hep Advances
Background and Aims: We evaluated the association between endoscopic outcomes following risankizumab induction and subsequent rates of hospitalization and surgery through 52 weeks of risankizumab (both doses) maintenance therapy in patients with Crohn’s ...
Brian G. Feagan, Jean-Frederic Colombel, Remo Panaccione, Stefan Schreiber, Marc Ferrante, Koji Kamikozuru, Christopher Ma, Wan-Ju Lee, Jenny Griffith, Namita Joshi, Kristina Kligys, Jasmina Kalabic, Si Xuan, Marla Dubinsky   +13 more
doaj   +1 more source

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial

Durable clinical remission, endoscopic healing, and biomarker normalization are key treatment goals for Crohn's disease. The selective anti-interleukin-23 p19 inhibitor risankizumab has demonstrated efficacy and safety in moderately to severely active ...
Kalabic, Jasmina, Neimark, Ezequiel, Wallace, Kori, Fujii, Toshimitsu, Abreu, Maria T, Torres, Joana, Kligys, Kristina, Rausch, Astrid, Liao, Xiaomei, Gao, Xiang, Song, Alexandra, Panaccione, Remo, Cao, Qian, Irving, Peter M, Axler, Jeffrey, Berg, Sofie, Ferrante, Marc, Zhou, Qing, Feagan, Brian   +18 more
core   +3 more sources

Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)

Frontiers in Immunology
IntroductionThe development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives of patients.
Luigi Gargiulo, Luigi Gargiulo, Luciano Ibba, Luciano Ibba, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Giovanni Damiani, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Santo R. Mercuri, Massimo Travaglini, Antonio Costanzo, Antonio Costanzo, Alessandra Narcisi   +26 more
doaj   +1 more source

Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Rheumatology and Therapy
Introduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors ...
Philip J. Mease, Richard B. Warren, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Iain B. McInnes   +8 more
doaj   +1 more source